CY1115321T1 - Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων - Google Patents

Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων

Info

Publication number
CY1115321T1
CY1115321T1 CY20141100111T CY141100111T CY1115321T1 CY 1115321 T1 CY1115321 T1 CY 1115321T1 CY 20141100111 T CY20141100111 T CY 20141100111T CY 141100111 T CY141100111 T CY 141100111T CY 1115321 T1 CY1115321 T1 CY 1115321T1
Authority
CY
Cyprus
Prior art keywords
vascular
antibodies directed
antibodies
angiotensin
chain fragments
Prior art date
Application number
CY20141100111T
Other languages
English (en)
Inventor
Thomas C Boone
Jonathan D Oliner
Eunkyung Lee
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40625974&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115321(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1115321T1 publication Critical patent/CY1115321T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Αποκαλυπτόμενοι είναι ειδικοί συνεργάτες σύνδεσης, όπως πλήρως ανθρώπινα αντισώματα, που συνδέονται προς αγγειοποιητίνη 1 ή/και αγγειοποιητική-2. Επίσης αποκαλυπτόμενα είναι θραύσματα βαριάς αλύσου, θραύσματα ελαφράς αλύσου και CDRs των αντισωμάτων, καθώς επίσης μέθοδοι κατασκευής και χρήσης των αντισωμάτων.
CY20141100111T 2008-02-20 2014-02-13 Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων CY1115321T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6663208P 2008-02-20 2008-02-20
US6194308P 2008-06-16 2008-06-16
US13936108P 2008-12-19 2008-12-19
EP09711869.9A EP2252632B1 (en) 2008-02-20 2009-02-20 Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof

Publications (1)

Publication Number Publication Date
CY1115321T1 true CY1115321T1 (el) 2017-01-04

Family

ID=40625974

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100111T CY1115321T1 (el) 2008-02-20 2014-02-13 Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων

Country Status (32)

Country Link
US (5) US8030025B2 (el)
EP (2) EP2679599B1 (el)
JP (1) JP5739163B2 (el)
KR (1) KR101600639B1 (el)
CN (1) CN102046657B (el)
AR (1) AR070453A1 (el)
AU (1) AU2009215804B2 (el)
BR (1) BRPI0907530B1 (el)
CA (2) CA2844188A1 (el)
CL (1) CL2009000379A1 (el)
CO (1) CO6290772A2 (el)
CR (1) CR11658A (el)
CY (1) CY1115321T1 (el)
DK (1) DK2252632T3 (el)
EA (1) EA022308B1 (el)
ES (2) ES2453342T3 (el)
HK (1) HK1149023A1 (el)
HR (1) HRP20140341T1 (el)
IL (1) IL207445A (el)
JO (1) JO2913B1 (el)
MA (1) MA32190B1 (el)
MX (1) MX2010009185A (el)
MY (1) MY156458A (el)
NZ (2) NZ600112A (el)
PE (1) PE20091571A1 (el)
PL (1) PL2252632T3 (el)
PT (1) PT2252632E (el)
RS (1) RS53262B (el)
SI (1) SI2252632T1 (el)
TW (1) TWI433683B (el)
WO (1) WO2009105269A1 (el)
ZA (1) ZA201006173B (el)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
SG10201605629VA (en) 2008-01-03 2016-08-30 Scripps Research Inst Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
DE102009053584A1 (de) * 2009-11-17 2011-05-19 Airbus Operations Gmbh Trägersystem zum Aufnehmen von Behältern in einem Fahrzeug und Verwendung eines Trägersystems in einem Flugzeug
CA2798273A1 (en) * 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9512220B2 (en) * 2011-04-05 2016-12-06 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
US20130330745A1 (en) * 2011-12-20 2013-12-12 Abbott Japan Co. Ltd. Methods of prognosis and diagnosis in sepsis
US20150044227A1 (en) * 2012-03-08 2015-02-12 Medimmune, Llc Methods of treatment with angiopoietin-2 antibodies
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
EP2970908B1 (en) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US10293023B2 (en) 2013-03-15 2019-05-21 Children's Medical Center Corporation Method of altering vascular permeability and uses thereof
EP2835380B2 (en) 2013-07-29 2021-04-07 Samsung Electronics Co., Ltd Method of blocking vascular leakage using an anti-Ang2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
ES2755129T3 (es) 2013-12-06 2020-04-21 Dana Farber Cancer Inst Inc Péptidos terapéuticos
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
WO2015139020A2 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
WO2016061551A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
KR20170082594A (ko) * 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019028012A2 (en) 2017-07-31 2019-02-07 Dana-Farber Cancer Institute, Inc. METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
BR112020026862A2 (pt) 2018-06-29 2021-04-20 Gensun Biopharma, Inc. antagonistas antitumorais de reguladores de pontos de verificação imunológica
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
EP3960763A4 (en) * 2019-08-14 2022-12-28 Pharmabcine Inc. ANTI-TIE 2 ANTIBODIES AND ITS USE
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
US11484027B2 (en) 2020-10-29 2022-11-01 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
WO2022225182A1 (ko) * 2021-04-23 2022-10-27 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5981726A (en) 1990-10-12 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US5889157A (en) * 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0528767B1 (en) 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
ES2227512T3 (es) * 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
US5837822A (en) 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ATE222291T1 (de) 1992-03-13 2002-08-15 Organon Teknika Bv Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
CA2131003A1 (en) * 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
AU4651893A (en) * 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
JPH06153984A (ja) 1992-11-27 1994-06-03 Morinaga & Co Ltd 抗体および抗体ｃＤＮＡ
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU8143094A (en) 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
AU717611B2 (en) 1994-10-28 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Tumor-specific antibody fragments, fusion proteins, and uses thereof
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20050287630A1 (en) 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6777540B1 (en) * 1996-09-02 2004-08-17 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US5977319A (en) 1996-10-21 1999-11-02 Cambridge Antibody Technology Limited Specific binding members for estradiol; materials and methods
WO1998018914A1 (en) 1996-10-31 1998-05-07 Duke University Soluble tie2 receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU6542898A (en) 1997-03-05 1998-09-22 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
WO1999045959A1 (en) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
JP2000080100A (ja) 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
EP1123398B1 (en) 1998-10-16 2005-08-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Molecular pathogenicide mediated plant disease resistance
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
EP1051620B1 (en) 1998-10-30 2006-06-07 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
ES2199804T3 (es) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
EP1181058A2 (de) 1999-05-27 2002-02-27 Max-Delbrück-Centrum Für Molekulare Medizin Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
NZ516258A (en) 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
ATE449109T1 (de) 1999-06-15 2009-12-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
DE60038132T2 (de) 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
CA2399080C (en) 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU2001233114A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20020048763A1 (en) * 2000-02-04 2002-04-25 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis
EP1130030A1 (en) 2000-03-02 2001-09-05 Roche Diagnostics Corporation Human erythroid differentiation related factor
JP4019615B2 (ja) * 2000-03-10 2007-12-12 富士ゼロックス株式会社 光磁気素子、光磁気ヘッドおよび磁気ディスク装置
AU4976001A (en) 2000-03-30 2001-10-15 Dyax Corp Mucin-1 specific binding members and methods of use thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
WO2005056601A2 (en) 2003-12-05 2005-06-23 Schreiber John R Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
MXPA03002918A (es) * 2000-10-02 2004-04-20 Arizeke Pharmaceuticals Inc Composiciones y metodos para el transporte de agentes biologicamente activos a traves de barreras celulares.
US20030166160A1 (en) * 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
EP1661986A1 (en) 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
DE10059930A1 (de) 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002060954A1 (en) * 2001-01-12 2002-08-08 Karolinska Innovations Ab Materials and methods for treatment of hepatitis c
EP1349935A2 (en) * 2001-01-12 2003-10-08 Incyte Genomics, Inc. Molecules for disease detection and treatment
AU2002253889A1 (en) 2001-02-02 2002-10-03 Arizeke Pharmaceuticals, Inc. Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules
US20030054407A1 (en) * 2001-04-17 2003-03-20 Peizhi Luo Structure-based construction of human antibody library
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
IL159015A0 (en) * 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
AU2002346127B2 (en) 2001-06-28 2008-05-29 Kyowa Hakko Kirin Co., Ltd. Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US20050260195A1 (en) 2001-10-04 2005-11-24 Xtl Biopharmaceuticals Ltd. Treatment of hepatitis B virus infection with human monoclonal antibodies
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AR036833A1 (es) 2001-10-18 2004-10-06 Bayer Corp Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
WO2003034990A2 (en) * 2001-10-25 2003-05-01 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
AU2002359568B2 (en) 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
WO2003048328A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
ATE394121T1 (de) * 2001-12-28 2008-05-15 Amgen Fremont Inc Verwendung von antikörpern gegen das muc18- antigen
EP1466623B1 (en) 2001-12-28 2009-04-22 Kyowa Hakko Kogyo Co., Ltd. Anti-fgf-8 antibodies against arthritis
JP2005516965A (ja) * 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
ES2289174T3 (es) * 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20040258699A1 (en) 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
JP2005533486A (ja) 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
JP4660189B2 (ja) 2002-07-03 2011-03-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
ES2442615T5 (es) * 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
WO2004024098A2 (en) 2002-09-16 2004-03-25 Abgenix, Inc. Method for the treatment of nephritis using anti-pdgf-dd antibodies
JP2006501856A (ja) * 2002-10-09 2006-01-19 インテグリジェン， インコーポレイテッド 組換え触媒ポリペプチドおよびその使用
US20040151724A1 (en) * 2002-10-31 2004-08-05 Julia Coronella-Wood Antibody fab fragments specific for breast cancer
ATE455853T1 (de) 2002-11-22 2010-02-15 Chugai Pharmaceutical Co Ltd Antikörper gegen geschädigtes gewebe
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
AU2003299581A1 (en) * 2002-12-02 2004-06-23 Abgenix, Inc. Antibodies against drugs of abuse
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
CA2508214A1 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
WO2005035732A2 (en) * 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
EP3000886A1 (en) * 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
DK1626992T3 (da) * 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
AU2004259398A1 (en) * 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
WO2005016111A2 (en) * 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
JP2007528721A (ja) * 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
EP1508576A1 (en) 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
EP2229955A1 (en) 2003-10-16 2010-09-22 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment using the same
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2236172A1 (en) * 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
KR20060121150A (ko) 2003-11-11 2006-11-28 추가이 세이야쿠 가부시키가이샤 인간화 항-ｃｄ47 항체
US7612179B2 (en) * 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
RU2006122946A (ru) 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
TW200605906A (en) 2004-05-11 2006-02-16 Chugai Pharmaceutical Co Ltd Remedy for thrombopenia
KR101456770B1 (ko) 2004-05-27 2014-10-31 크루셀 홀란드 비.브이. 광견병 바이러스를 중화시킬 수 있는 결합 분자 및 그 용도
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
NZ579543A (en) * 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
CA2573505C (en) 2004-07-14 2013-06-25 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
AU2005263331B8 (en) 2004-07-20 2011-06-16 Symphogen A/S Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture
US7910100B2 (en) 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2009262199B2 (en) * 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EA022308B1 (ru) 2015-12-30
US20120034237A1 (en) 2012-02-09
RS53262B (en) 2014-08-29
ES2660381T3 (es) 2018-03-22
JP2011525104A (ja) 2011-09-15
US20120258122A1 (en) 2012-10-11
AU2009215804B2 (en) 2013-04-18
CA2844188A1 (en) 2009-08-27
CN102046657A (zh) 2011-05-04
JP5739163B2 (ja) 2015-06-24
NZ600112A (en) 2013-08-30
MX2010009185A (es) 2011-02-23
IL207445A0 (en) 2010-12-30
US20130336992A1 (en) 2013-12-19
BRPI0907530B1 (pt) 2021-09-28
US10336820B2 (en) 2019-07-02
US20090226447A1 (en) 2009-09-10
MA32190B1 (fr) 2011-04-01
CO6290772A2 (es) 2011-06-20
PE20091571A1 (es) 2009-10-21
US8030025B2 (en) 2011-10-04
PT2252632E (pt) 2014-04-07
EP2252632A1 (en) 2010-11-24
AR070453A1 (es) 2010-04-07
MY156458A (en) 2016-02-26
SI2252632T1 (sl) 2014-03-31
BRPI0907530A2 (pt) 2015-07-28
CA2715324A1 (en) 2009-08-27
EA201001335A1 (ru) 2011-08-30
NZ587230A (en) 2012-08-31
TWI433683B (zh) 2014-04-11
AU2009215804A1 (en) 2009-08-27
CR11658A (es) 2010-10-11
ZA201006173B (en) 2011-10-26
DK2252632T3 (da) 2014-04-07
WO2009105269A1 (en) 2009-08-27
HRP20140341T1 (hr) 2014-05-09
JO2913B1 (en) 2015-09-15
KR20100118143A (ko) 2010-11-04
CL2009000379A1 (es) 2012-02-24
CN102046657B (zh) 2014-04-09
US20170081398A1 (en) 2017-03-23
EP2679599A1 (en) 2014-01-01
EP2679599B1 (en) 2018-01-03
KR101600639B1 (ko) 2016-03-07
HK1149023A1 (en) 2011-09-23
PL2252632T3 (pl) 2014-06-30
ES2453342T3 (es) 2014-04-07
IL207445A (en) 2015-09-24
EP2252632B1 (en) 2014-01-15
TW200940092A (en) 2009-10-01
US8221749B2 (en) 2012-07-17
CA2715324C (en) 2014-05-13

Similar Documents

Publication Publication Date Title
CY1115321T1 (el) Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων
CY1122646T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
CY1116886T1 (el) C-met αντισωματα
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
CY1114784T1 (el) Αντισωματα εναντι σκληροστινης
CY1124028T1 (el) Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
ATE485307T1 (de) Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
CR20120105A (es) Proteínas terapéuticas de unión a dll4
EA201070888A1 (ru) Антитела и их производные
NZ709353A (en) Antibodies that bind il-4 and/or il-13 and their uses
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1